Edotreotide is a ligand that selectively targets SSTR2 and can competitively bind to the receptor. Edotreotide mediates the targeted delivery, while modificated with radionuclides (such as 90Y, 177Lu, and 68Ga) to SSTR-positive tumors and induces tumor cell apoptosis by releasing beta rays. Edotreotide has strong tumor targeting and precise killing activity. Edotreotide is used in the synthesis of radionuclide-drug conjugates (RDCs) and is widely used in the field of neuroendocrine tumors (such as metastatic carcinoids, lung and thymus NETs)[1][2][3].
Molecular Weight:
1421.64
Purity:
98.15
CAS Number:
[204318-14-9]
Formula:
C65H92N14O18S2
Target:
Radionuclide-Drug Conjugates (RDCs)
Application Notes:
Peptides
* VAT and and shipping costs not included. Errors and price changes excepted
